结肠癌中p—mTOR、p—p70S6K的表达与临床病理意义(4)
[14] Murayama T，Inokuchi M，Takagi Y，et al.Relation between outcomes and localisation of p-mTOR expression in gastric cancer[J].Br J Cancer，2009，100(5)：782-788.
[15] Gille H，Kowalski J，Li B，et al.Analysis of biological effects and signaling properties of Flt-1(VEGFR-1) and KDR(VEGFR-2).A reassessment using novel receptor-specific vascular endothelial growth factor mutants[J].J Biol Chem，2001，276(5)：3222-3230.
[16] Melling N，Simon R，Izbicki J R，et al.Expression of phospho-mTOR kinase is abundant in colorectal cancer and associated with left-sided tumor localization[J].Int J Clin Exp Pathol，2015，8(6)：7009-7015.
[17] Ueng S H，Chen S C，Chang Y S，et al.Phosphorylated mTOR expression correlates with poor outcome in early-stage triple negative breast carcinomas[J].Int J Clin Exp Pathol，2012，5(8)：806-813.
[18] Yamazaki T，Akada T，Niizeki O，et al.Puromycin-insensitive leucyl-specific aminopeptidase(PILSAP) binds and catalyzes PDK1，allowing VEGF-stimulated activation of S6K for endothelial cell proliferation and angiogenesis[J].Blood，2004，104(8)：2345-2352.
[19] Xu Y，Luo Q，Lin T，et al.U12，a UDCA derivative，acts as an anti-hepatoma drug lead and inhibits the mTOR/S6K1 and cyclin/CDK complex pathways[J].PLoS One，2014，9(12)：e 113479.
[20] Wang X，Li W，Williams M，et al.Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase[J].EMBO J，2001，20(16)：4370-4379.
[21] Park C M，Park M J，Kwak H J，et al.Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways[J].Cancer Res，2006，66(17)：8511-8519.
(收稿日期：2017-09-25) (本文編辑：程旭然), http://www.100md.com(赵溢斐 周逢强 徐宏)
[15] Gille H，Kowalski J，Li B，et al.Analysis of biological effects and signaling properties of Flt-1(VEGFR-1) and KDR(VEGFR-2).A reassessment using novel receptor-specific vascular endothelial growth factor mutants[J].J Biol Chem，2001，276(5)：3222-3230.
[16] Melling N，Simon R，Izbicki J R，et al.Expression of phospho-mTOR kinase is abundant in colorectal cancer and associated with left-sided tumor localization[J].Int J Clin Exp Pathol，2015，8(6)：7009-7015.
[17] Ueng S H，Chen S C，Chang Y S，et al.Phosphorylated mTOR expression correlates with poor outcome in early-stage triple negative breast carcinomas[J].Int J Clin Exp Pathol，2012，5(8)：806-813.
[18] Yamazaki T，Akada T，Niizeki O，et al.Puromycin-insensitive leucyl-specific aminopeptidase(PILSAP) binds and catalyzes PDK1，allowing VEGF-stimulated activation of S6K for endothelial cell proliferation and angiogenesis[J].Blood，2004，104(8)：2345-2352.
[19] Xu Y，Luo Q，Lin T，et al.U12，a UDCA derivative，acts as an anti-hepatoma drug lead and inhibits the mTOR/S6K1 and cyclin/CDK complex pathways[J].PLoS One，2014，9(12)：e 113479.
[20] Wang X，Li W，Williams M，et al.Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase[J].EMBO J，2001，20(16)：4370-4379.
[21] Park C M，Park M J，Kwak H J，et al.Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways[J].Cancer Res，2006，66(17)：8511-8519.
(收稿日期：2017-09-25) (本文編辑：程旭然), http://www.100md.com(赵溢斐 周逢强 徐宏)
参见：首页 > 医疗版 > 疾病专题 > 消化内科 > 肠道疾病 > 类癌及类癌综合征 > 结、直肠癌